DGAP-News: Vivoryon Therapeutics N.V. / Key word: Study Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Provides Update on Business and Progress of Varoglutamstat Clinical Development in. | October 18, 2021
DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Study Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Provides Update on Business and Progress of Varoglutamstat Clinical Development
About Vivoryon Therapeutics N.V.
Vivoryon is a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the live of medically underserved patients suffering from severe diseases. We leverage our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings before they cause irreversible damage. Beyond our lead program, varoglutamstat, which is in Phase 2 clinical development to treat Alzheimer s disease, we have established a solid pipeline of orally available small molecule inhibitors for various indications including cancer, inflammatory diseases and fibrosis. www.vivoryon.com
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Provides Update on Financial Guidance
vom 29.06.2021, 01:11 Uhr
Bild: pixabay.com
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Provides Update on Financial Guidance
29.06.2021 / 01:11
Vivoryon Therapeutics Provides Update on Financial Guidance
Halle (Saale) / Munich, Germany, June 29, 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines, today announced an update on its financial guidance. According to current estimates, the Company expects the recently signed regional licensing agreement with Simcere Pharmaceutical Group Ltd. to have an impact on Vivoryon s previously communicated cash-reach of Q3 2022, which is anticipated to be extended for at least three quarters until Q2 2023. A detailed update on anticipated working capital requirements and resulting timelines will be giv